Arkolith/Insider Trading/TSHA/Form 4

Nagendran Sukumar

President and Head of R&D, DirectorTaysha Gene Therapies, Inc. (TSHA) · full profile →Form 4 · filed Jan 4, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2024Grant(A)864K—$0898K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2024Grant(A)864K—$0864K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-24-000809) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML